Newborn Screening at Mayo Clinic Laboratories
Newborn screening is intended to detect serious health conditions in babies for which early intervention can greatly improve healthy development and positive outcomes.
Own your lab, own your future - Insights
The laboratory is the cornerstone for health systems that offer complex care. Learn how lab ownership is a key driver of patient care excellence and health system growth.
New tests launched in November - Insights
In November 2022, Mayo Clinic Laboratories announced eighteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Novel panel identifies toxins linked to asthma and GI diseases - Insights
Melissa Snyder, Ph.D., explains how Mayo Clinic Laboratories' EDN panel improves the evaluation of certain patients with asthma and autoimmune digestive disorders. EDN is the first laboratory test that provides a marker of...
Updated testing algorithms for plasma cell proliferative disorders [Test in Focus] - Insights
Xinjie Xu, Ph.D., co-director of Mayo's Genetics and Genomics Laboratory, explains Mayo Clinic Laboratories' updated approach to testing for risk stratification of patients newly diagnosed with plasma cell proliferative disorders, such as...
Liquid biopsy cancer testing - Insights
Learn how the pioneering approach used in liquid biopsy testing available through Mayo Clinic Laboratories enables individualized insights that drive personalized care.
Assay enhances and simplifies M-proteins screening: David Murray, M.D., Ph.D. - Insights
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the...
Thrombotic Microangiopathies (TMA) [Test in Focus] - Insights
Meera Sridharan, M.D., Ph.D., explains Mayo Clinic Labs’ testing approach for atypical hemolytic uremic syndrome (aHUS). The serological complement panel examines nine analytes to gain a thorough understanding of the complement cascade to...
Neurofascin 155 IgG4 Antibody Test [Test in Focus] - Insights
John Mills, Ph.D., explains Mayo Clinic Laboratories' new neurofascin 155 (NF155) IgG4 antibody test, which is the first commercially available test in the U.S. to use flow cytometry to detect for NF155 antibodies and confirm diagnosis of...
Mayo Clinic and National Decision Support Company unveil CareSelect Lab™ to provide real-time medical guidance when ordering clinical lab tests. The tool assists health care providers with appropriate ordering of lab testing, improving...